ECSP045114A - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Info

Publication number
ECSP045114A
ECSP045114A EC2004005114A ECSP045114A ECSP045114A EC SP045114 A ECSP045114 A EC SP045114A EC 2004005114 A EC2004005114 A EC 2004005114A EC SP045114 A ECSP045114 A EC SP045114A EC SP045114 A ECSP045114 A EC SP045114A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hgh
Prior art date
Application number
EC2004005114A
Other languages
Spanish (es)
Inventor
Rory F Finn
Wei Liao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP045114A publication Critical patent/ECSP045114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una modificación química de la hormona de crecimiento humana (hGH) y a variantes agonistas de la misma mediante la cual se pueden cambiar las propiedades químicas y/o fisiológicas de la hGH. La hGH PEGilada puede tener una mayor duración de residencia en plasma, una menor velocidad de aclaramiento, mejor estabilidad, menos antigenicidad o una combinación de estas característicasThe present invention relates to a chemical modification of human growth hormone (hGH) and agonist variants thereof by which the chemical and / or physiological properties of hGH can be changed. PEGylated hGH may have a longer residence duration in plasma, a lower clearance rate, better stability, less antigenicity or a combination of these characteristics

EC2004005114A 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES ECSP045114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ECSP045114A true ECSP045114A (en) 2004-07-23

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005114A ECSP045114A (en) 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
PT3025726T (en) * 2002-01-18 2020-01-09 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USES OF THE SAME
KR20050093856A (en) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
JP2008502301A (en) * 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ Peptide conjugation
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2642214T3 (en) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugation of peptides by transglutaminase
KR20070042567A (en) * 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 Glycerol Branched Polyethylene Glycol Human Growth Hormone Conjugates, Methods for Making the Same and Methods for Using the Same
BRPI0519430A2 (en) * 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CN101400646A (en) * 2005-11-08 2009-04-01 Ambrx公司 Promoters for modifying unnatural amino acids and unnatural amino acid polypeptides
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0713963A2 (en) * 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
JP2010507382A (en) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ IL-21 mutant
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
MX344559B (en) 2008-04-29 2016-12-20 Ascendis Pharma As Pegylated recombinant human growth hormone compounds.
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof
AR072850A1 (en) * 2008-07-31 2010-09-22 Pharmaessentia Corp PEPTIDO-POLYMER CONJUGATES
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
JP5766118B2 (en) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymeric alpha-hydroxyaldehyde and ketone reagents and conjugation methods
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX337432B (en) 2009-12-15 2016-03-04 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier.
RS59459B1 (en) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (en) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
KR20130115086A (en) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP6820841B2 (en) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (en) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (en) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilization of somatotropins by modifying cysteine residues
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK0851925T3 (en) * 1995-09-21 2005-11-28 Genentech Inc Human Growth Hormone Variants
ES2297889T3 (en) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
EA008505B1 (en) 2007-06-29
AP2004003050A0 (en) 2004-06-30
EA200700431A1 (en) 2008-02-28
CN1608079A (en) 2005-04-20
EP1453859A2 (en) 2004-09-08
RS53104A (en) 2006-10-27
JP2006321808A (en) 2006-11-30
PL374354A1 (en) 2005-10-17
KR20050044858A (en) 2005-05-13
BR0214451A (en) 2006-05-30
TNSN04090A1 (en) 2006-06-01
MXPA04004809A (en) 2004-08-11
NO20042182L (en) 2004-08-11
WO2003044056A2 (en) 2003-05-30
CO5580794A2 (en) 2005-11-30
OA13063A (en) 2006-11-10
JP2005525302A (en) 2005-08-25
GEP20063860B (en) 2006-06-26
HRP20040448A2 (en) 2006-02-28
WO2003044056A3 (en) 2003-08-21
EA200400565A1 (en) 2005-06-30
IL162031A0 (en) 2005-11-20
CA2467731A1 (en) 2003-05-30
MA27544A1 (en) 2005-10-03
KR20070072924A (en) 2007-07-06
HUP0500997A2 (en) 2007-11-28
ZA200403907B (en) 2007-12-27
AU2002356990A1 (en) 2003-06-10
IS7268A (en) 2004-05-17

Similar Documents

Publication Publication Date Title
ECSP045114A (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES
EP1196444B8 (en) Exendin-4 conjugates and their medical use
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AP2003002918A0 (en) Pulmonary administration of chemically modified insulin.
DE602004017252D1 (en) Body care compositions Compositions containing structured conditioner premix
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002245413A1 (en) Athletic clothing with sting reduction padding
IL166171A0 (en) Blood clot-targeted nanoparticles
WO2003057135A3 (en) Aqueous compositions containing metronidazole
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
PL1522312T3 (en) Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin.
HUP0401289A3 (en) Cyclic ketones as blocking agents
BRPI0412803A (en) unglycosylated human alpha-fetoprotein, production methods and uses thereof
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
BRPI0313645A2 (en) inhalation compositions with high drug ratios.
WO2004085471A3 (en) Glp-2 derivatives
TR200601608T1 (en) Long-acting compositions comprising an avermectin combination.
ZA200205880B (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.
AU2002327440A1 (en) Treatment of type i diabetes
AP2248A (en) Treatment of HI-virus infections with oxidised blood proteins.
DE60235473D1 (en) Implantable miniature connectors
WO2007081409A3 (en) Super-elastic nanostructures and methods of fabrication thereof
CR7346A (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES